Originally planned for Orlando, FL on October 1-4, we are pleased to reschedule this event as part of the AABB Virtual Annual Meeting on November 6-7! Join hundreds of exercise
enthusiasts within the AABB community for the annual Run for Research in support of the AABB Foundation’s mission. The Run for Research offers several options for our community to take part in the fun and race your way!
Virtual Run / Walk – Connect with other blood and biotherapies professionals worldwide taking strides to advance research in the field. Log your time any day of the meeting. Registration $55 includes a souvenir t-shirt. Shirts cannot be mailed internationally.
Sleep In – Hit the pillow instead of the pavement! Sleep in for research!
Share the fun you're having by posting photos and videos using the #AABB22 hashtag on AABB’s social media, Facebook, Twitter, LinkedIn and Instagram.
*Register by October 24th and receive your t-shirt in time for the event.
Run for Research Sponsors:
The AABB Foundation fuels innovative research in transfusion medicine and related biotherapies for the benefit of patients and donors. For almost 40 years, the Foundation has provided critical funding to emerging researchers seeking future medical breakthroughs for patients across pediatrics, oncology, cardiology and transplantation.
Participate in the 2022 Virtual Run for Research during the AABB Virtual Annual Meeting to help us support and honor researchers working to make a difference in the lives of patients and donors worldwide. All proceeds benefit the AABB Foundation.
The NBF R&D Summit is a three-part series focused on forward-thinking research discussions that can impact the blood and biotherapies field. Executives, senior leadership, researchers and regulators throughout our community are invited to join us for the three-part series. Start your Saturday, Sunday and Monday with a stimulating research discussion prior to engaging in the meeting’s education sessions.
October 1, 2, and 3
7:00 am - 8:30 am
Registration: $100
* Monday’s public forum is open to all meeting attendees free of charge on a first-come-first-served basis. Full Summit registrants will have reserved seats with the first working group of their choice.
R&D Summit Sponsors:
Saturday, October 1
7:00am – 8:30am
Orange County Convention Center
Room 314
Buffy-Coat Platelets & Non-DEHP Plastics: Opportunities & Challenges
Throughout the past few years, buffy coat platelets (BC-PLTs) have become a focal point of interest in the United States (U.S.) blood product industry.
Blood product suppliers view BC-PLTs as an opportunity to provide more platelets to an already strained blood supply. Device manufacturers struggle with this concept as BC-PLTs are not recognized as a platelet product in the U.S.
In 2025, the European market will no longer allow the plasticizer di(2-ethylhexyl)phthalate (DEHP) to be used in blood collection systems. The only way for the continued use of DEHP in blood bag sets is to apply for authorization (AfA) at the European Chemical Agency ECHA. Within the U.S., it is not clear if similar plans for the exclusion of DEHP is imminent. The U.S. blood community would like to determine which clinical trials and other research would be required in the regulatory pathway to non-DEHP storage containers. With many questions surrounding these two topics, this session will discuss some concerns regarding timeline and downstream impacts on blood and biotherapy manufacturing and patients.
Join this session to learn about experiences from others and possible pathways for buffy-coat platelets as a platelet product in the U.S. and the impact of DEHP elimination on blood and biotherapies. A panel comprised of representatives from the Blood Transfusion Association, European Blood Alliance and Canadian and U.S. blood establishments will discuss these pressing issues necessary for strategic planning.
Panelists
Dana Devine, PhD
Director, Centre for Blood Research
Chief Scientific Officer, Canadian Blood Services
Professor, Pathology and Laboratory Medicine
Associate Member, Biochemistry and Molecular Biology
Member, UBC Centre for Blood Research
Stefan Kolb
Vice President
Blood Transfusion Association
Pierre Tiberghien, MD, PhD
President, European Blood Alliance;
Professor of Medicine, Université
de Franche-Comté;
Senior Advisor, Etablissement Français du Sang
Rob Van Tuyle
Executive Vice President, Chief Operations Officer
Vitalant
Sunday, October 2, 2022
7:00am – 8:30am
Orange County Convention Center
Room 314
Blood Supply Shortages: Donor Opportunities and Momentum Toward More Precise Patient Care
Remuneration of Blood Donors
With a blood supply shortage made much more apparent as a result of the global pandemic, blood and plasma suppliers are struggling to meet the demand for products. The psychology
of donor motivation is unclear and blood collection facilities have relied on various forms of incentives to maintain a donor system. While plasma collections for future manufacturing have relied on monetary remuneration, doing the same for blood
collection has been divisive. This discussion will present opposing sides of donor remuneration.
Presenters:
James Stacey Taylor, MA, PhD
Professor
Applied ethics (especially medical ethics), ethical theory, and questions surrounding the moral limits of markets
The College of New Jersey
Pampee P. Young, MD, PhD
Chief Medical Officer
Biomedical Services
American Red Cross
Evolving Toward Precision Transfusion Medicine and Biotherapies
Research advancing patient and donor care is driving a shift toward more precise transfusion medicine and biotherapies. However, existing
operations and logistics are lacking to support a more professional donor pool. This discussion will address some critical questions:
Presenter:
Brian Custer, PhD, MPH
Director, Vitalant Research Institute
Senior Vice President Research and Scientific Programs, Vitalant
Adjunct Professor, Laboratory Medicine University of California San Francisco
Universal Blood Donor Genotyping Platform – Overview and Updates from the Blood transfusion Genomics Consortium (BGC)
The Blood transfusion Genomics Consortium (BGC) is an international partnership
between blood services, research institutions and industry leaders. The Consortium aims to improve the safety and efficiency of blood and platelet transfusion by introducing cutting-edge genomics technology into routine clinical practice and the development
of DNA-based assays, software solutions, and infrastructure required to implement donor and patient genotyping at a global scale.
As Principal Investigators of the Consortium, Drs. Montemayor Garcia and Lane will present an overview of
goals and objectives as well as progress to date. How might this global initiative impact blood donation, operations and patient care in the future?
Presenters:
Celina Montemayor Garcia, MD, PhD
Medical Officer, Centre for Innovation
Canadian Blood Services
Principal Investigator, Blood transfusion Genomics Consortium (BGC)
William (Bill) Lane, MD, PhD, A(ACHI)
Associate Professor,
Harvard Medical School
Faculty, Brigham and Women’s Hospital
Director, Tissue Typing Laboratory
Principal Investigator, Blood transfusion Genomics Consortium (BGC)
Monday, October 3, 2022
7:00am – 8:30am
Orange County Convention Center
Room 314
New this year, the NBF collaborated with NHLBI to bring a public forum to the AABB Annual Meeting. Monday’s program, “Research Priorities for Transfusion Medicine”, follows the recent NHLBI State of the Science in Transfusion Medicine (SoS in TM) symposium and is an opportunity to discuss in more detail the research priorities outlined by the six working groups. Attendees can provide input on the research areas and help prioritize them.
*Monday’s public forum is open to all meeting attendees free of charge on a first-come-first-served basis. Full Summit registrants will have reserved seats with the first working group of their choice.
Research Priorities for Transfusion Medicine
Priorities based on the advances in the field and new considerations, such as SARS-CoV-2 and other emerging infectious diseases, need to be reevaluated, Research priorities were last evaluated
in the 2015 National Heart, Lung, and Blood Institute (NHLBI) of NIH State of the Science in Transfusion Medicine (SoS in TM). R&D Summit attendees have a unique opportunity to engage with expert scientists in the field to help shape a research
agenda for the next 3-10 years.
In August 2022, NHLBI and the Office of the Assistant Secretary of Health (OASH) of the Department of Health and Human Services held a SoS in TM symposium to identify current basic, translational, and clinical research priorities in transfusion medicine. The goal of the symposium was to identify research priorities in six overarching areas that, if addressed in the next 3-10 years, would increase and diversify the volunteer blood donor pool, identify which blood products from which donors would best meet the clinical needs of specific transfusion recipient populations, and help ensure safe and effective transfusion strategies.
During this Summit program, choose your own adventure to explore the same six overarching areas discussed at the SoS in TM! Attendees may participate the entire time (70 minutes) with one working group or may move around and join different round table discussions. Following the NBF R&D Summit, the priorities will be further refined and developed into manuscripts for publication in transfusion medicine-focused journals.
Round Table Discussion Areas:
Monday, October 3rd
11:30 am – 1:00 pm
Orange County Convention Center - Room 340
Lunch provided.
Program agenda is subject to change.
For almost four decades AABB’s National Blood Foundation has infused the transfusion medicine and biotherapies fields with innovative science and pioneering leaders. NBF-funded research helps shape the scientific footprint of AABB’s Annual Meeting. This premier scientific showcase brings that science into one program and features the research of a select group of experts who began their careers with NBF funding. AABB and NBF Board members, NBF committee members and prior grant recipients are invited to this exclusive program. The NBF Award for Innovative Research recipient and recently inducted Hall of Fame members will present updates on their research programs. Invitation Only
Program Moderator:
James D. Gorham, MD, PhD
Medical Director, Transfusion Medicine Services
Chief, Division of Laboratory Medicine, and Professor, Department of Pathology
University of Virginia
Presenters:
“Hydroxyurea and Transfusion (HAT): Pilot Study of Combination Therapy for Patients with Sickle Cell Anemia”
Robert Nickel, MD, MSc
Assistant Professor
Division of Hematology
Children’s National Hospital
“The Promise and Challenges of Targeting Humoral Immunity using T Cell Immunotherapy”
Vijay Bhoj, MD, PhD
Assistant Professor
Pathology and Laboratory Medicine at the Hospital of the University of
Pennsylvania
Perelman School of Medicine at the University of Pennsylvania
“Role of Heme and Iron in Shaping Macrophage Inflammatory Response and Functions in Hemoglobinopathies”
Francesca Vinchi, PhD
Assistant Member
Head of Iron Research Program
New York Blood Center
“Novel Therapeutics for Hemophilia B: A Rational Pursuit of Bioengineered Factor IX Variants with Enhanced Clotting Activity”
Benjamin Samelson-Jones,
MD, PhD
Assistant Professor
Children's Hospital of Philadelphia
Perelman School of Medicine at the University of Pennsylvania
“Role of Storage Temperature for Platelet Transfusion Efficacy”
Moritz
Stolla, MD
Director, Platelet Transfusion Research, Assistant Member
BloodworksNW Research Institute
Assistant Professor, Div. of Hematology, Dept. of Medicine
University of Washington School of Medicine
Associate Medical Director, Swedish Medical Center, Blood Transfusion Service
Use your invitation code to add this exclusive program to your Annual Meeting registration.
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
